ISMO

LOE Approaching

isosorbide mononitrate

NDAORALTABLET
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT06616623Phase 1Recruiting

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Started Dec 2024
24 enrolled
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
NCT05399537Phase 3Recruiting

Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

Started Jul 2024
40 enrolled
Regional Citrate Anticoagulation (RCA)Continuous Renal Replacement Therapy (CRRT)Acute Kidney Injury (AKI)
NCT07121634N/AActive Not Recruiting

Cervical Ripening With Misoprostol vs Isosorbide Mononitrate ; A Parallel -Arm Randomized Controlled Trial

Started Jan 2024
NCT05538091Phase 2Recruiting

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Started May 2023
48 enrolled
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPARP Inhibitor+1 more
NCT05651828Phase 1Recruiting

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Started Mar 2023
34 enrolled
Advanced Basal Cell Carcinoma